BMEA
Closed
Biomea Fusion Inc
1.72
-0.08 (-4.44%)
Last Update: 01 Jul 2025 23:13:00
Yesterday: 1.8
Day's Range: 1.63 - 1.8
Send
sign up or login to leave a comment!
When Written:
31.01
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing precision medicines to treat patients with genetically defined cancers. The company's proprietary drug discovery platform integrates genomics, bioinformatics, and artificial intelligence to identify and develop targeted therapies for specific genetic alterations in cancer cells. Biomea Fusion's lead product candidate is BMF-219, a selective inhibitor of the NRG1 fusion protein, which is being evaluated in Phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 2018 and is headquartered in Irvine, California.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








